Ulipristal
- Generic Name
- Ulipristal
- Brand Names
- Ella, Ellaone, Esmya, ellaOne
- Drug Type
- Small Molecule
- Chemical Formula
- C28H35NO3
- CAS Number
- 159811-51-5
- Unique Ingredient Identifier
- 6J5J15Q2X8
- Background
Ulipristal is a selective progesterone receptor modulator used for the purposes of emergency contraception (Ella) and for the treatment of uterine fibroids (Fibristal). It is a derivative of 19-norprogesterone and has both antagonistic and partial agonist activity at the progesterone receptor. It also binds to glucocorticoid receptor, however compared to mif...
- Indication
As the product Ella (available in Canada and the US), ulipristal is indicated for use as emergency contraception after unprotected intercourse or possible contraceptive failure when administered within 120 hours (5 days) after unprotected intercourse or a known or suspected contraceptive failure. As the product Fibristal (available in Canada), ulipristal is ...
- Associated Conditions
- Moderate Uterine Fibroids, Severe Uterine Fibroids
- Associated Therapies
- Emergency Contraception
Study of the Safety and Efficacy of Ulipristal Acetate (UPA) Used Daily as a Contraceptive
- First Posted Date
- 2017-09-28
- Last Posted Date
- 2019-10-09
- Lead Sponsor
- Health Decisions
- Target Recruit Count
- 300
- Registration Number
- NCT03296098
- Locations
- 🇺🇸
Women & Infants Hospital of Rhode Island, Providence, Rhode Island, United States
🇺🇸New York University, School of Medicine, New York, New York, United States
🇺🇸Columbia University, New York, New York, United States
Ulipristal Versus Placebo for Women With Bleeding Induced by Mirena
- Conditions
- Interventions
- First Posted Date
- 2017-06-14
- Last Posted Date
- 2018-05-03
- Lead Sponsor
- University of Campinas, Brazil
- Target Recruit Count
- 32
- Registration Number
- NCT03186586
- Locations
- 🇧🇷
University of Campinas, Campinas, SP, Brazil
Intervention to End Recurrent Unscheduled Bleeding Trial
- Conditions
- Interventions
- First Posted Date
- 2017-04-18
- Last Posted Date
- 2018-08-31
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 65
- Registration Number
- NCT03118297
- Locations
- 🇺🇸
Washington University School of Medicine in St. Louis, Saint Louis, Missouri, United States
Compare Daily Ulipristal Acetate and Combined Oral Contraceptive Effects on Breast Epithelial Cell Proliferation
- Conditions
- Interventions
- First Posted Date
- 2016-10-04
- Last Posted Date
- 2020-02-07
- Lead Sponsor
- Columbia University
- Target Recruit Count
- 29
- Registration Number
- NCT02922127
- Locations
- 🇺🇸
Weill Cornell Medical Center, New York, New York, United States
🇺🇸Columbia University Irving Medical Center, New York, New York, United States
Ulipristal Use in Chinese Population
- Conditions
- Interventions
- First Posted Date
- 2016-07-07
- Last Posted Date
- 2020-04-09
- Lead Sponsor
- Queen Mary Hospital, Hong Kong
- Target Recruit Count
- 31
- Registration Number
- NCT02825719
- Locations
- 🇭🇰
Department of Obstetrics and Gynaecology, Queen Mary Hospital, Hong Kong, Hong Kong
Study of Ulipristal Acetate in Female Patients With Moderately or Severely Impaired Renal Function, Compared With Matched Healthy Female Subjects
- First Posted Date
- 2015-12-18
- Last Posted Date
- 2018-02-08
- Lead Sponsor
- Allergan
- Target Recruit Count
- 19
- Registration Number
- NCT02634437
- Locations
- 🇺🇸
Division of Clinical Pharmacology, University of Miami, Miami, Florida, United States
🇺🇸Clinical Pharmacology of Miami, Miami, Florida, United States
🇺🇸Orlando Clinical Research Center, Orlando, Florida, United States
IVF Outcome Following Treatment With Ulipristal Acetate for Myomatous Uterus After at Least One IVF Failure
- Conditions
- Interventions
- First Posted Date
- 2015-11-10
- Last Posted Date
- 2016-07-12
- Lead Sponsor
- Sheba Medical Center
- Target Recruit Count
- 20
- Registration Number
- NCT02601196
Ulipristal Acetate In Disease Charcot-Marie-Tooth Type of 1A
- First Posted Date
- 2015-11-09
- Last Posted Date
- 2022-07-25
- Lead Sponsor
- University Hospital, Strasbourg, France
- Target Recruit Count
- 23
- Registration Number
- NCT02600286
- Locations
- 🇫🇷
Unité de pathologie neuro-musculaire, Paris, France
🇫🇷Département de Neurologie Centre de Référence des Maladies Neuromusculaires Grand Est (CERNEST) Hôpital de Hautepierre, Strasbourg, France
🇫🇷Service d'Explorations et pathologies neuro- musculaires, Besançon, France
Adenomyosis and Ulipristal Acetate
- First Posted Date
- 2015-10-27
- Last Posted Date
- 2022-09-27
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 26
- Registration Number
- NCT02587000
- Locations
- 🇫🇷
AP-HP, Bicêtre Hospital, Le Kremlin Bicêtre, France
Impact of Combined Hormonal Contraceptives on UPA
- Conditions
- Interventions
- First Posted Date
- 2015-10-16
- Last Posted Date
- 2019-11-08
- Lead Sponsor
- Oregon Health and Science University
- Target Recruit Count
- 36
- Registration Number
- NCT02577601
- Locations
- 🇺🇸
Oregon Health & Science University, Portland, Oregon, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.